Literature DB >> 25209987

Why doesn't reducing exacerbations decrease COPD mortality?

Guy Brusselle1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25209987     DOI： 10.1016/S2213-2600(14)70163-8

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  3 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.

Authors:  Guy Brusselle; David Price; Kevin Gruffydd-Jones; Marc Miravitlles; Dorothy L Keininger; Rebecca Stewart; Michael Baldwin; Rupert C Jones
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-15

3.  A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Juthaporn Cowan; Logan Gaudet; Sunita Mulpuru; Vicente Corrales-Medina; Steven Hawken; Chris Cameron; Shawn D Aaron; D William Cameron
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.